Loading
Discovered ALK mutations in neuroblastoma and led the trials bringing crizotinib and lorlatinib to children.
Yael Mossé was first author of the 2008 discovery of ALK mutations in neuroblastoma and has led the clinical translation of ALK inhibition in children through the Children's Oncology Group and NANT consortium, including the phase 1 trials of crizotinib and lorlatinib and the addition of lorlatinib to front-line high-risk neuroblastoma therapy in COG ANBL1531. She leads the developmental therapeutics programme at CHOP.
| Title | Journal | Year |
|---|---|---|
| Identification of ALK as a major familial neuroblastoma predisposition gene | Nature | 2008 |
| Lorlatinib for ALK-driven relapsed or refractory neuroblastoma (NANT 2015-02) | Nature Medicine | 2023 |
Shares Children's Hospital of Philadelphia, ALK, Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
Shares Lorlatinib, ALK, Small-molecule kinase inhibitors and the tag alk.
Shares Children's Hospital of Philadelphia and the tag paediatric.
Shares Neuroblastoma (paediatric) and the tag paediatric.
Shares Children's Hospital of Philadelphia and the tag paediatric.
Shares Neuroblastoma (paediatric) and the tag neuroblastoma.